(Q24235385)

English

Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes

scientific article (published 1996-09-01)

In more languages

Statements

scholarly article

0 references

0 references

Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes (English)

0 references

acute coronary syndrome

1 reference

based on heuristic

inferred from title

2

object named as

Jaume Marrugat

0 references

author name string

Xavier Bosch

1

0 references

Juan Sanchis

3

0 references

publication date

1 September 1996

0 references

Cochrane Database of Systematic Reviews

0 references

Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patien

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibati

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

A comparison of dual vs. triple antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndrome: results of the ELISA-2 trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Efficacy of abciximab for patients undergoing balloon angioplasty: data from Japanese evaluation of c7E3 Fab for elective and primary PCI organization in randomized trial (JEPPORT).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Bivalirudin for patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acu

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Early abciximab administration in acute myocardial infarction treated with primary coronary intervention.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Prehospital therapy with the platelet glycoprotein IIb/IIIa inhibitor eptifibatide in patients with suspected acute coronary syndromes: the Bochum feasibility study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Comparison of antiplatelet effect of loading dose of clopidogrel versus abciximab during coronary intervention

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the [...]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Early versus delayed, provisional eptifibatide in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

A comparison of two invasive strategies in patients with non-ST elevation acute coronary syndromes: results of the Early or Late Intervention in unStable Angina (ELISA) pilot study. 2b/3a upstream therapy and acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Facilitated PCI in patients with ST-elevation myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Impact of early tirofiban administration on myocardial salvage in patients with acute myocardial infarction undergoing infarct-related artery stenting.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Effect of tirofiban on C-reactive protein in non-ST-elevation myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST t

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Recepto

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Bivalirudin during primary PCI in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Potential economic impact of glycoprotein IIb-IIIa inhibitors in improving outcomes of patients with acute ischemic coronary syndromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Facilitated percutaneous coronary intervention (PCI) in patients with acute ST-elevation myocardial infarction: comparison of prehospital tirofiban versus fibrinolysis before direct PCI.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYM

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Impacts of glycoprotein IIb/IIIa inhibition on QT dispersion after successful percutaneous coronary intervention.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Prehospital versus periprocedural abciximab in ST-elevation myocardial infarction treated by percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Use of abciximab prevents microcirculatory impairment in patients treated with coronary angioplasty for unstable angina: results of a prospective randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING Study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

The effect of glycoprotein IIb/IIIa receptor inhibitor on the microcirculation in patients undergoing high-risk coronary stenting; a prospective, randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Coronary plaque disruption.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Comparison of fondaparinux and enoxaparin in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Long-Term Results After the Glycoprotein IIb/IIIa Inhibitor Abciximab in Unstable Angina: One-Year Survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Prior aspirin use predicts worse outcomes in patients with non–ST-elevation acute coronary syndromes11This study was sponsored by COR Therapeutics Inc., South San Francisco, California; and Schering-Plough Research Institute, Kenilworth, New Jersey

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (Abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization fn1fn1This study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Comparison of pre-hospital combination-fibrinolysis plus conventional care with pre-hospital combination-fibrinolysis plus facilitated percutaneous coronary intervention in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Abciximab improves 6-month clinical outcome after rescue coronary angioplasty

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

21 January 2018

Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early ReoPro administration in myocardial infarction (ERAMI) trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Coronary artery stenting for suboptimal PTCA results in acute myocardial infarction in patients treated with Abciximab: early and six-month outcome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 t

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Early abciximab administration before primary percutaneous coronary intervention improves infarct-related artery patency and left ventricular function in high-risk patients with anterior wall myocardial infarction: a randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study. The PARAGON B International Steering Committee

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Usefulness of abciximab for treatment of early coronary artery stent thrombosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Coronary Stenting plus Platelet Glycoprotein IIb/IIIa Blockade Compared with Tissue Plasminogen Activator in Acute Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiplatelet therapy in therapy-resistant unstable angina. A pilot study with REO PRO (c7E3)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome man

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events i

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002130.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/14651858.CD002130.PUB2

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24235385&oldid=1622304988"